Rotavirus vaccine potentially costeffective in Afghanistan

Rotavirus vaccine potentially costeffective in Afghanistan PharmacoEconomics & Outcomes News 792, p26 - 2 Dec 2017 Rotavirus vaccine potentially cost effective in Afghanistan Introduction of a rotavirus vaccination programme is likely to be cost effective in Afghanistan, according to findings of a study published in Vaccine. The ProVac Initiative UNIVAC model was used to evaluate the potential impact and cost effectiveness of a national rotavirus immunization programme with a two- dose schedule of Rotarix (RIX 4414) in ten birth cohorts in Afghanistan between 2017 and 2026, compared with no rotavirus vaccination, from government and societal perspectives, with and without Gavi (Vaccine Alliance) support. The assumed vaccine price was $2.02 per dose. Over the 10-year period, rotavirus vaccination was predicted to avert over one million cases of rotavirus infection, and approximately 660 000 outpatient visits, 50 000 rotavirus-related hospital admissions, 650 000 disability-adjusted life-years (DALYs) and 12 000 deaths. It would save $1.35 million in treatment costs from the government perspective and $2.80 million from a societal perspective. Without the Gavi subsidy, the estimated incremental cost-effectiveness ratio (ICER) for rotavirus vaccination versus no vaccination was $82 per DALY averted from the government perspective and $80 per DALY averted from the societal perspective. With the Gavi subsidy, ICERs were $31 and $29 per DALY averted, respectively. It was estimated that the annual cost of the rotavirus vaccination programme would account for 2.8% of the total immunisation budget and 0.1% of total health expenditure in Afghanistan in 2017. "In summary, this analysis demonstrates that rotavirus vaccination is likely to be highly cost-effective and avert a substantial health and economic burden of disease in Afghanistan," said the authors. * 2017 US dollars Anwari P, et al. Potential impact and cost-effectiveness of rotavirus vaccination in Afghanistan. Vaccine : 26 Oct 2017. Available from: URL: j.vaccine.2017.10.058 803284215 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 PharmacoEconomics & Outcomes News Springer Journals

Rotavirus vaccine potentially costeffective in Afghanistan

1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial